Search Results - "MEISNER, P. D"

A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain by WALLACE, M. S, ROWBOTHAM, M. C, KATZ, N. P, DWORKIN, R. H, DOTSON, R. M, GALER, B. S, RAUCK, R. L, BACKONJA, M. M, QUESSY, S. N, MEISNER, P. D

“…Nerve injury results in increases in spinal glutamate, which opens the NMDA ionophore channel, causing an influx of calcium. A glycine-binding site must be…”
Get full text

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab by McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., Grauer, A.

“…Summary This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low…”
Get full text

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis by Saag, Kenneth G, Petersen, Jeffrey, Brandi, Maria Luisa, Karaplis, Andrew C, Lorentzon, Mattias, Thomas, Thierry, Maddox, Judy, Fan, Michelle, Meisner, Paul D, Grauer, Andreas

“…Among postmenopausal women with osteoporosis and a high risk of fracture, treatment with the monoclonal antibody romosozumab for 12 months followed by…”
Get full text

Romosozumab Treatment in Postmenopausal Women with Osteoporosis by Cosman, Felicia, Crittenden, Daria B, Adachi, Jonathan D, Binkley, Neil, Czerwinski, Edward, Ferrari, Serge, Hofbauer, Lorenz C, Lau, Edith, Lewiecki, E. Michael, Miyauchi, Akimitsu, Zerbini, Cristiano A.F, Milmont, Cassandra E, Chen, Li, Maddox, Judy, Meisner, Paul D, Libanati, Cesar, Grauer, Andreas

“…Romosozumab binds sclerostin, increases bone formation, and decreases bone resorption. Postmenopausal women with osteoporosis were assigned to romosozumab or…”
Get full text

Predictors of Placebo Response in Pooled Lamotrigine Neuropathic Pain Clinical Trials by Irizarry, Michael C, Webb, David J, Ali, Zahid, Chizh, Boris A, Gold, Michael, Kinrade, Frances J, Meisner, Paul D, Blum, David, Silver, Marianne T, Weil, John G

“…OBJECTIVESOne limitation of neuropathic pain clinical trials is the often large and variable extent of response in the placebo group, possibly obscuring true…”
Get full text